Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Connecticut ephedrine ban

This article was originally published in The Tan Sheet

Executive Summary

Connecticut ephedrine ban: State Department of Consumer Protection proposes rule to prohibit the sale of ephedrine in non-drug form. The rule would classify "products containing ephedrine, ephedrine alkaloids, or their isomers and analogs, and dietary supplements from which ephedrine, ephedrine alkaloids, or their isomers and analogs can be derived, including but not limited to ephedra, ephedra sinica, ma huang and epitonin" as a "banned hazardous substance." FDA-approved OTC drugs would be exempt. A hearing on the issue was held July 18. Other states such as Florida and Texas have taken similar actions. Ohio also initiated a ban but later reversed it...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel